Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

CD37 inhibitor

DRUG CLASS:

CD37 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

177Lu-lilotomab satetraxetan (4)

177Lu-lilotomab satetraxetan (4)

›

ERBB3 expression	Renal Cell Carcinoma	ERBB3 expression	Renal Cell Carcinoma	177Lu-lilotomab satetraxetan Sensitive: D – Preclinical 177Lu-lilotomab satetraxetan Sensitive : D	177Lu-lilotomab satetraxetan Sensitive: D – Preclinical 177Lu-lilotomab satetraxetan Sensitive : D
ERBB3 expression	Prostate Cancer	ERBB3 expression	Prostate Cancer	177Lu-lilotomab satetraxetan Sensitive: D – Preclinical 177Lu-lilotomab satetraxetan Sensitive : D	177Lu-lilotomab satetraxetan Sensitive: D – Preclinical 177Lu-lilotomab satetraxetan Sensitive : D
ERBB3 expression	Colorectal Cancer	ERBB3 expression	Colorectal Cancer	177Lu-lilotomab satetraxetan Sensitive: D – Preclinical 177Lu-lilotomab satetraxetan Sensitive : D	177Lu-lilotomab satetraxetan Sensitive: D – Preclinical 177Lu-lilotomab satetraxetan Sensitive : D
ERBB3 expression	Ovarian Cancer	ERBB3 expression	Ovarian Cancer	177Lu-lilotomab satetraxetan Sensitive: D – Preclinical 177Lu-lilotomab satetraxetan Sensitive : D	177Lu-lilotomab satetraxetan Sensitive: D – Preclinical 177Lu-lilotomab satetraxetan Sensitive : D